Mark Cascione

Statistics

Publications

Citations

1.3K

H-Index

Active since

2011

Affiliations

Urology Associates(Current)

Ono Pharmaceutical (United States)

NeuroRx Research (Canada)

Neurology Associates

McGill University

Mark Cascione is an author at Urology Associates specializing in multiple sclerosis, multiple sclerosis pharmacotherapy, and multiple sclerosis therapy.

Publications per year

2011–2021

Publications

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Tanuja Chitnis, Brenda Banwell, Ludwig Kappos et al. · The Lancet Neurology · 2021 · 81 citations

Medicine, Neurology, Pediatrics +12

Cladribine tablets added to IFN-β in active relapsing MS

Xavier Montalbán, Thomas Leist, Bruce A. Cohen et al. · Neurology Neuroimmunology & Neuroinflammation · 2018 · 63 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Gavin Giovannoni, Jeffrey Cohen, Alasdair Coles et al. · Neurology · 2016 · 62 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

Erin E. Longbrake, Yang Mao‐Draayer, Mark Cascione et al. · Multiple Sclerosis Journal · 2020 · 43 citations · Full text

Life Sciences, Immunology, Pharmacology +16

1–5 of 11